News

Boehringer in HCV partnership
Enlarge image

BusinessGermany

Boehringer in HCV partnership

14.03.2013 - Boehringer Ingelheim and US firm Presidio Pharmaceuticals will combine their drugs against Hepatitis C.

The firms said they entered a non-exclusive collaboration for a 12-week Phase IIa trial of an oral combination treatment for patients with chronic hepatitis C virus (HCV) infection starting in Q2/2013. San Francisco-based Presidio will contribute its second-generation NS5A inhibitor PPI-668 whilst Boehringer Ingelheim will chip in its HCV protease inhibitor faldaprevir (BI201335) and its non-nucleoside HCV polymerase inhibitor BI207127. The combination will be tested with or without ribavirin.

"The study will assess the potential of this three-drug oral regimen to achieve high rates of sustained viral clearance in hepatitis C patients, with good tolerance.", said Dr Nathaniel Brown, DMO of Presidio, who will have primary responsibility for the trial. Both companies will retain all rights to their compounds. Data from the trials are anticipated in Q4/2013.

The current standard treatment for patients with hepatitis C genotype-1 infection is pegylated interferon-alfa (ribavirin) and an HCV protease inhibitor.

© eurobiotechnews.eu/tg

BusinessSwitzerlandUK

23.04.2014 In an effort to focus on key businesses, pharma giant Novartis is joining forces with long-time rival GlaxoSmithKline in a multi-billion Euro asset exchange and an OTC joint venture.

FinanceSwedenFrance

18.04.2014 Oxthera AB, a Swedish biopharma company with a focus on rare diseases, has gained a SEK70m cash injection to continue its clinical programme for primary hyperoxaluria.

FundingEU

17.04.2014 The European Parliament has given green light to the second Innovative Medicines Initiative with the aim to advance pharmacological research and development, particularly in areas of unmet medical need.

BusinessGermanyFrance

15.04.2014 German flavour and scent specialist Symrise has announced its plans to acquire French pet-food ingredients maker Diana Group for €1.3bn.

BioeconomySpain

14.04.2014 Spanish Neol Biosolutions and the Center for Second Generation Biofuels are starting a partnership to scale-up Neol's waste-to-oil technology.

EvidenceUKSwitzerland

11.04.2014 There is no evidence that neuraminidase inhibitors Tamiflu and Relenza prevent complications of influenza or reduce hospital admissions. In addition, it is unclear whether they can stop the spread of influenza in case of outbreaks, says a report by the Cochrane Collaboration.

BusinessSwitzerlandSpain

09.04.2014 Roche is extending its involvement in the area of point-of-care diagnostics by taking over US company Iquum. In the field of epigenetics, the Swiss pharma company has started a cooperation with the Spanish company Oryzon.

Status ReportSwitzerland

08.04.2014 The Swiss Biotech Report 2014 presented in Zurich sees an encouraging upturn in the country's biotech scene. However, the acceptance of the mass immigration initiative poses a significant threat.

NanobiotechnologyItaly

07.04.2014 Scientists from the University of Udine have designed, produced and tested a prototype for a "DNA origami" nanorobot that can potentially deliver biological activators in-vivo.

EpidemicEUFranceGermanyItaly

02.04.2014 As the Ebola epidemic in Guinea worsens, Europe is deploying the specialists of EMLab to provide diagnostics at the focus of the outbreak.

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)344.00 GBP12.6%
  • THERAMETRICS (CH)0.11 CHF10.0%
  • ACTIVE BIOTECH (S)35.60 SEK9.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • GENFIT (F)22.42 EUR-8.1%
  • BAVARIAN NORDIC (D)13.63 EUR-6.4%

TOP

  • BIOTECH PHARMACON (N)19.00 NOK67.4%
  • WILEX (D)0.81 EUR37.3%
  • E-THERAPEUTICS (UK)28.00 GBP34.9%

FLOP

  • CYTOS (CH)0.16 CHF-94.1%
  • BIONOR PHARMA (N)2.17 NOK-45.7%
  • DIAGENIC (N)0.77 NOK-38.9%

TOP

  • SILENCE THERAPEUTICS (UK)257.25 GBP6331.2%
  • IXICO (UK)66.50 GBP734.4%
  • PLETHORA (UK)10.00 GBP614.3%

FLOP

  • CYTOS (CH)0.16 CHF-96.1%
  • EVOCUTIS (UK)0.22 GBP-91.9%
  • ADDEX (CH)1.96 CHF-71.0%

No liability assumed, Date: 24.04.2014